Making a Difference, Here & Beyond
The community invests in Dell Med. In return, it’s our responsibility — one we take seriously — to be agents for change and to show real impact.
OUR WORK
More Information
PARTICIPATE
COLLABORATE
Creating a New Kind of Doctor
We recruit and train physician leaders as comfortable taking on systemic challenges in health as caring for individual patients.
ARE YOU ONE?
Improving Care. Improving Health.
We’re here to make health — including health care — better. The end goal is a complete revolution in how people get and stay healthy.
WHAT IT MEANS
Discovery to Impact — Faster
We reward creative thinking and encourage rapid experimentation, using collaborative programs to speed promising research to market.
SEE HOW
More Information
Let’s Do Big Things Together
True health demands that the whole work in harmony, which is why we’re dedicated to partnership. Indeed, we can’t achieve our goals without it.
EXPLORE OPTIONS
Meet Dell Med
We’re rethinking the role of academic medicine in improving health — and doing so with a unique focus on our community.
ABOUT US
More Information
Make an Appointment Directory Give Faculty Students
CME

Psychiatry & Behavioral Sciences Grand Rounds: Alcohol & Opioid Addiction

Location: Zoom

Date: Tuesday, June 15, 2021

Time: 12–1 p.m.

Contact: Renee Collins

About the Event

This installment of Psychiatry and Behavioral Sciences Grand Rounds features George F. Koob, Ph.D., presenting “Alcohol and Opioid Addiction: The Gain in Brain is in the Pain.” Koob is the director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) — National Institutes of Health

For Zoom information or general questions, contact Renee Collins via email or at 512-495-5617.

Learning Objectives

By the end of this presentation, the audience participant should be able to:

  • Review the heuristic framework of addiction as a 3-stage cycle.
  • Discuss the construct of hyperkatifeia associated with the withdrawal/negative affect stage of the addiction cycle and explain how it drives addiction.
  • Identify neurocircuits/neurotransmitters associated with hyperkatifeia and describe how they contribute to allostatic forces that cause the emotional pain of addiction.

Target Audience

  • Primary: Psychiatrists, social workers, psychologists, nurses and other mental health professionals
  • Secondary: Other health care professionals

Attributes/Competencies

This activity has been designed to promote some of the following desired physician attributes and competencies:

  • ACGME: Patient Care; Medical Knowledge; Practice-Based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; Systems-Based Practice
  • IOM: Provide patient-centered; Work in interdisciplinary teams; Employ evidenced-based practice; Apply quality improvement; Utilize informatics
  • IECC: Interprofessional Teamwork & Team-based Practice; Interprofessional Communication; Values & Ethics for Interprofessional Practice

Speaker Disclosure

George F. Koob, Ph.D., speaker for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Planner Disclosure

Robert E. Feinstein, M.D.; Roshni Koli, M.D.; Jorge Almeida, M.D.; Lowell McRoberts, M.D.; Cathy Stacey, Ph.D.; Kathryn Flowers; and Renee Collins, planners of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

The CME Advisory Committee, reviewers for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Jeffrey Newport, M.D., M.S., MDiv, planner for this educational activity, received grants/ research support from Eli Lilly, Glaxo SmithKline (GSK), Janssen, Sage Therapeutics, Takeda Pharmaceuticals, and Wyeth Pharmaceuticals.

He has received honorarium from GSK, Janssen, Sage Therapeutics and is on the speaker’s bureau of Astra-Zeneca, Eli Lilly, GSK, Pfizer, WyethPharmaceuticals.

Steve Strakowski, M.D., planner for this educational activity, received grants/research support from Janssen research foundation (to UT) and is a consultant for Sunovion (DSMB chair).

Charles B. Nemeroff, M.D., Ph.D., planner for this educational activity, is a consultant for ANeuroTech (division of Anima BV), Taisho Pharmaceutical, Inc., Takeda, Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage Threaputics, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, and Corcept Therapeutics Pharmaceuticals Company.

He is a stock shareholder (directly purchased) of Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness.

Nemeroff is on the Scientific Advisory Boards for ANeuroTech (division of Anima BV), Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, and on the Board of Directors of Xhale Smart, Inc.

He holds patents for the following: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas at Austin Dell Medical School designates this internet live course for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.